More than 200 years ago, the first vaccine was developed for smallpox, and now, the disease has been eradicated worldwide. And in the United States, the transmission of poliovirus, measles and rubella have been eliminated. These are examples of tremendous scientific progress, and through our growing understanding of how these and other diseases work at the molecular level, many new therapeutic and preventative vaccines have been developed.
A new PhRMA report, “Medicines in Development for Vaccines,” offers insight into the more than 250 vaccines currently in development, designed to prevent and treat illness. More than two-thirds of the vaccines in the last 25 years have been developed in the United States – underscoring the commitment of America’s biopharmaceutical research companies despite a particularly challenging research and development process.
Vaccines in development today will help prevent or treat a number of conditions, including:
- 124 for infectious diseases; and
- 105 for cancer.
Thanks to the perseverance of researchers and scientists, patients are reaping the benefits of innovative medicines to protect against many more life-threatening diseases in years to come.
View the full report here.
Hannah Mooney Hannah is a Senior Manager of Public Affairs at PhRMA developing paid media programs and campaigns as well as assisting other PhRMA team members to cultivate a values-driven messaging platform on the value of the industry and the medicines our companies bring to the health care system. In a former life, she worked in grassroots advocacy and voter contact, supporting Members of Congress, their campaigns, and public affairs organizations with their legislative initiatives in addition to having worked in the U.S. Senate in communications. Hannah enjoys being outdoors and exploring all the city has to offer, teaching cycling classes, and finding new restaurants with good food and better patios in the District.